HEALTHY INDIVIDUALS NEEDED TO HELP STOP EVZILLA!
The University of Maryland School of Medicine is conducting a Phase 1 clinical trial (DMID 23-0005) for Acute Flaccid Myelitis (AFM).
Acute flaccid myelitis (AFM) is an uncommon but serious neurologic condition caused by an enterovirus infection. It affects the nervous system, specifically the area of the spinal cord called gray matter, which causes the muscles and reflexes in the body to become weak. Increases in AFM cases have occurred in 2014, 2016, and 2018 in the U.S.
Participants aged 18 to 49 will receive one of three dosages of EV68-228-N, a monoclonal antibody infusion. The trial spans four months with nine visits, prioritizing safety through monitoring, diary recording, lab tests, ECGs, and safety event tracking. This marks the first human use of EV68-228-N, with rigorous preparation and transportation to ensure product quality.
Participants can receive compensation up to $1,600. Your involvement advances AFM research.
Ready to get started?
Call: 410-706-8800 (8am-4pm)
Email: clintrial@som.umaryland.edu
Or complete our contact form.